Prediction: Moderna Stock Will Soar 100% by 2030
The company could enter a fresh growth phase.
Moderna (NASDAQ: MRNA) experienced a significant boost for investors during the early stages of the pandemic, thanks to its pioneering role in the coronavirus vaccine market. However, once demand for the vaccine, then the company's sole commercialized product, dwindled, so did the firm's earnings. Consequently, Moderna's stock stagnated for a few years.
But recently, the company has turned things around. Moderna's cost restructuring initiatives are showing positive results, and its pipeline candidates are advancing towards completion. This has caught the attention of investors, who were particularly impressed with the late-stage trial data for Moderna's personalized cancer vaccine.
Moreover, the company has secured approval for new products, the latest being an mRNA flu vaccine, set to launch for the current season. The biotech firm even projects that its revenue for the current year could surge by up to 10%. Taking all these developments into account, my forecast is that Moderna stock will witness a 100% increase by 2030. To delve deeper into this case, please continue reading.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
